KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
Bijal Shah(Boston College), Roch Houot(Inserm), Patrick J. Stiff(Loyola University Medical Center), Francesca Milletti, Martha Arellano(Memorial Sloan Kettering Cancer Center), Remus Vezan(National University of Misiones), Mehrdad Abedi(UC Davis Comprehensive Cancer Center), Deepa Jeyakumar(Dana-Farber Cancer Institute), Gary J. Schiller(Fred Hutch Cancer Center), Thibaut Leguay(Centre Hospitalier Universitaire de Bordeaux), Tong Shen(Qingdao University of Science and Technology), Olalekan O. Oluwole(Vanderbilt University), Jinghui Dong(Chinese PLA General Hospital), Monique C. Minnema(University Medical Center Utrecht), Maria R. Baer(University of Maryland, Baltimore), Chaoling Feng(Kite (United States)), Aaron C. Logan(University of California, San Francisco), Ryan D. Cassaday(University of Washington), Nicolas Boissel(Inserm), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Behzad Kharabi Masouleh(Erytech Pharma (France)), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Armin Ghobadi(Washington University in St. Louis), William G. Wierda(University of Maryland, Baltimore), Michael R. Bishop(University of Chicago), Yi Lin, Max S. Topp(Universitätsklinikum Würzburg), Jae H. Park(Memorial Sloan Kettering Cancer Center), Marion Subklewe(LMU Klinikum), John M. Rossi(Amgen (United States)), Kristen M. O’Dwyer(University of Rochester Medical Center)
Cited by 795
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k